Drug Type Biological products |
Synonyms |
Target |
Mechanism CD226 inhibitors(CD226 molecule inhibitors) |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatocellular Carcinoma | Phase 2 | JP | 28 Oct 2019 | |
Hepatocellular Carcinoma | Phase 2 | US | 28 Oct 2019 | |
Advanced Malignant Solid Neoplasm | Phase 1 | US | 28 Oct 2019 | |
Advanced Malignant Solid Neoplasm | Phase 1 | JP | 28 Oct 2019 | |
Leiomyosarcoma | Phase 1 | JP | 28 Oct 2019 | |
Leiomyosarcoma | Phase 1 | US | 28 Oct 2019 | |
Squamous Cell Carcinoma of Head and Neck | Phase 1 | US | 28 Oct 2019 | |
Squamous Cell Carcinoma of Head and Neck | Phase 1 | JP | 28 Oct 2019 | |
Uterine Cervical Cancer | Phase 1 | US | 28 Oct 2019 | |
Uterine Cervical Cancer | Phase 1 | JP | 28 Oct 2019 |
Phase 1 | 2 | vwnrxunscr(xhgzhcpwwj) = icnccsimii elhnraldak (yubytkmkbw, hstiwkfojm - ixotxblwhg) View more | - | 31 Aug 2021 |